1. Home
  2. FT vs TLSI Comparison

FT vs TLSI Comparison

Compare FT & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Franklin Universal Trust

FT

Franklin Universal Trust

HOLD

Current Price

$8.00

Market Cap

199.8M

Sector

Finance

ML Signal

HOLD

Logo TriSalus Life Sciences Inc.

TLSI

TriSalus Life Sciences Inc.

HOLD

Current Price

$2.61

Market Cap

270.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FT
TLSI
Founded
1988
2010
Country
United States
United States
Employees
N/A
102
Industry
Trusts Except Educational Religious and Charitable
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
199.8M
270.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
FT
TLSI
Price
$8.00
$2.61
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$7.00
AVG Volume (30 Days)
45.7K
476.6K
Earning Date
01-01-0001
05-12-2026
Dividend Yield
7.85%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$35.45
Revenue Next Year
N/A
$37.58
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.37
$2.20
52 Week High
$8.35
$7.95

Technical Indicators

Market Signals
Indicator
FT
TLSI
Relative Strength Index (RSI) 37.16 23.53
Support Level $7.83 N/A
Resistance Level $8.06 $5.41
Average True Range (ATR) 0.08 0.30
MACD -0.02 -0.22
Stochastic Oscillator 7.81 18.77

Price Performance

Historical Comparison
FT
TLSI

About FT Franklin Universal Trust

Franklin Universal Trust is a closed-end management investment company focused on providing high current income while preserving capital. Its secondary objective is to achieve income growth through dividend increases and capital appreciation. The fund invests in two asset classes: high-yield bonds and utility stocks. It applies fundamental research to build a diversified high-yield bond portfolio and targets utility companies with attractive dividend yields and a history of increasing dividends.

About TLSI TriSalus Life Sciences Inc.

TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.

Share on Social Networks: